Investment Rating - The report assigns an "Outperform" rating to multiple companies in the discretionary consumption sector, including Nike, Li Ning, Midea Group, JD Group, Haier Smart Home, Gree Electric, Anta Sports, and many others [1]. Core Insights - The report highlights that overseas consumer earnings releases have led to stock price volatility, with A/H shares anticipating a recovery in discretionary consumption in 2026 [1]. - The performance of various sectors is analyzed, with gaming, U.S. hotels, snacks, and retail showing positive trends, while luxury goods and overseas cosmetics are experiencing declines [4][12]. - The report notes that the gaming sector saw a strong increase in gross gaming revenue, with a year-on-year growth of 24%, exceeding market expectations [6][14]. Sector Performance Summary - **Gaming Sector**: Increased by 5.5%, driven by strong January gross gaming revenue growth and positive earnings from MGM China [6][14]. - **U.S. Hotels**: Also up by 5.5%, with Marriott and Hilton showing positive earnings forecasts [6][14]. - **Snacks**: Grew by 3.6%, with companies like Youyou Foods and Qiaqia Foods reporting significant growth expectations [6][14]. - **Retail Sector**: Increased by 3.5%, led by Walmart and Target, which exceeded market sales forecasts [8][14]. - **Domestic Sportswear**: Rose by 2.6%, with Li Ning benefiting from its partnership with the Chinese Olympic Committee [8][14]. - **Credit Card Sector**: Gained 2.3%, supported by strong earnings from Visa and Mastercard [8][14]. - **Domestic Cosmetics**: Increased by 2.1%, benefiting from overall strength in the beauty and skincare sector [8][14]. - **Luxury Goods**: Slightly up by 0.9%, influenced by a rebound in the U.S. market [8][14]. - **Overseas Cosmetics**: Decreased by 5.7%, with concerns over the sustainability of growth for Estée Lauder [9][15]. - **Pet Sector**: Down by 0.7%, with companies like Guai Bao Pet and Zhongchong Co. experiencing declines [8][14]. - **Gold and Jewelry**: Fell by 1.2%, affected by fluctuations in gold prices [8][14]. Valuation Analysis - The report indicates that the valuation of various sectors remains below their historical averages, with expected P/E ratios for 2025 showing significant discounts compared to the past five years [10].

Investment Rating - The report maintains a positive outlook on e.l.f. Beauty, raising the full-year net sales growth guidance from 18%-20% to 22%-23% due to the strong contribution from the Rhode acquisition [2][9]. Core Insights - e.l.f. Beauty achieved a 38% year-over-year increase in net sales for FY26Q3, reaching $489.5 million, with the Rhode acquisition contributing approximately $128 million [2][9]. - The core organic net sales growth was only about 2%, which is below expectations, primarily due to short-term softness in key international markets like the UK and Germany [2][9]. - The company has adjusted its global consumption growth expectation down to 6% from 8%, reflecting a marginal weakening in the broader consumer environment [2][9]. - The adjusted EBITDA rose by 79% to $123 million, representing 25% of net sales, indicating strong operational performance [2][9]. Performance Summary - e.l.f. Beauty has achieved year-over-year net sales growth for 28 consecutive quarters, positioning it among the few publicly-listed companies in the consumer sector capable of sustaining such prolonged high growth [2][9]. - The strong performance is driven by an excellent brand portfolio strategy, particularly the significant contribution from Rhode, alongside organic growth from the core business through a value proposition of premium quality at accessible pricing [2][9]. Cost Structure and Profitability - The gross margin in FY26Q3 decreased by 30 basis points to 71%, mainly due to higher tariff costs, partially offset by pricing and product mix optimization [3][10]. - The ratio of selling, general, and administrative (SG&A) expenses to net sales declined from 54% to 51%, benefiting from improved marketing spend efficiency [3][10]. - Marketing and digital investment as a percentage of net sales decreased from 27% to 21%, but is expected to rebound to around 27% in the second half of the fiscal year due to increased investment in major brand campaigns [3][10]. Brand Performance - The e.l.f. Cosmetics brand saw an 8% year-over-year increase in U.S. consumption, significantly outpacing the overall color cosmetics category growth of 4% [4][11]. - The company has established a dominant 22% market share in the face makeup segment, with significant growth potential remaining in lip and eye categories [4][11]. - Acquired brands like Rhode have achieved record launches in Sephora, and Naturium and e.l.f. SKIN have outperformed the overall U.S. skincare category growth [4][11]. Innovation and Marketing - e.l.f. continues to drive product innovation through community insights, with new products priced competitively against high-end counterparts [5][12]. - Breakthrough marketing campaigns have generated over 4 billion impressions, showcasing the company's effective marketing strategies [5][12]. International Market Potential - International sales currently account for approximately 20% of total sales, indicating substantial growth potential compared to the industry average of over 70% [6][13]. - The company has established a comprehensive distribution network in Germany and is expanding its presence in premium markets like Australia/New Zealand with the Rhode brand [6][13].

Investment Focus - The report emphasizes that both A-shares and Hong Kong stocks are in an upward trend with a phase of consolidation, indicating a healthier market environment [1][35] - The first trading week of February showed signs of stabilization in A-shares with reduced turnover, while the Hang Seng TECH Index experienced a decline of approximately 6.5% [1][35] Market Outlook - The report is optimistic about a potential recovery in the Chinese equity market leading up to the Spring Festival, driven by proactive policy support and a stabilizing "policy put" below 4,100 points for the Shanghai Composite [2][36] - The overall short-selling turnover in Hong Kong is around 19%, with the Hang Seng TECH Index seeing a quick rebound in short-selling turnover to 21%, suggesting a potential for a near-term rebound [2][36] - Strategic investors, particularly insurers, are increasing their exposure to Chinese equities due to the low risk-free yield in China, making equities more attractive compared to bonds and real estate [2][36] Investment Strategy - The recommended strategy is to remain invested through the holiday, taking advantage of the Spring Festival "red-envelope" rally and using recent market pullbacks as an opportunity to increase exposure [2][37] - The report highlights the importance of focusing on structural investment opportunities within the Chinese equity market [2][37] Sector Focus - The report suggests a focus on technology sectors, particularly commercial aerospace, AI hardware, and sectors benefiting from the "anti-involution" and "going abroad" trends, which are expected to show performance recovery [3][4] - Consumer sectors such as automotive, tourism, and textiles are highlighted as key areas for investment during the Spring Festival [4] - The report also points to the potential for recovery in cyclical industries, including chemicals, engineering machinery, and real estate, as seasonal policies are expected to boost demand [4]

Investment Rating - The report assigns a positive investment rating to Coherent, indicating an outperform expectation over the next 12-18 months [19]. Core Insights - Coherent delivered an outstanding performance in FY2Q26, achieving revenue of $1.69 billion, surpassing the consensus estimate of $1.64 billion, and setting a new record high. Non-GAAP EPS reached $1.29, exceeding the market expectation of $1.20. The non-GAAP gross margin climbed to 39%, reflecting strong profitability driven by lower raw material costs and improved operational efficiency [1][8]. Summary by Sections Financial Performance - In FY2Q26, Coherent's revenue was $1.69 billion, exceeding expectations and marking a historical high. Non-GAAP EPS was $1.29, above the anticipated $1.20. The gross margin increased to 39%, up 24 basis points quarter-over-quarter and 77 basis points year-over-year, primarily due to cost reductions and efficiency improvements in the datacenter and communications segments [1][8]. Business Segments - The datacenter business is the core growth driver, accounting for over 70% of total revenue. This segment saw a 14% quarter-over-quarter and 36% year-over-year revenue increase, fueled by strong demand for 800G and 1.6T optical modules. The company has made significant progress in OCS and CPO, securing orders from major AI datacenter clients [2][9]. Order Demand - The order-to-shipment ratio for the datacenter business exceeds 4:1, with demand visibility at an all-time high. Orders are scheduled through the end of 2026, with many new orders extending into 2027. Long-term demand forecasts from major clients cover the next two to three years, enhancing demand visibility and supporting future revenue growth [3][10]. Capacity Expansion - Coherent aims to double its internal InP production capacity by Q4 2026, currently achieving 80% of this target ahead of schedule. The 6-inch InP production line offers significant advantages, including a fourfold increase in chip output compared to 3-inch wafers and lower unit costs. The company has secured multiple suppliers to ensure raw material availability [4][11]. Future Outlook - For FY3Q26, Coherent expects revenue between $1.7 billion and $1.84 billion, aligning with market consensus. The non-GAAP gross margin is projected at 38.5%-40.5%, maintaining profitability. Non-GAAP EPS is anticipated to reach $1.28-$1.48, exceeding the consensus of $1.4. Strong customer demand and expanding production capacity are expected to drive robust revenue growth in upcoming quarters [5][12].

Investment Rating - The report maintains an "Outperform" rating for Visa with a target price of US$400.60, indicating a potential upside of 21.8% from the current price of US$328.93 [2][7]. Core Insights - In 1Q FY26, Visa's total revenue reached US$15.17 billion, a 14.0% year-over-year increase, slightly above expectations. Net revenue, after deducting client incentives, grew 14.6% year-over-year to US$10.90 billion, also exceeding forecasts [3][11]. - The growth in revenue was driven by strong performance in Commercial and Money Movement Solutions (CMS) and Value-Added Services (VAS), with CMS revenue increasing by 20% year-over-year and VAS revenue up 28% year-over-year [3][11]. - Visa's stablecoin strategy has evolved significantly, with the company expanding its stablecoin card issuance to over 50 countries and achieving an annualized settlement volume of approximately US$4.6 billion by the end of 2025 [5][12]. - Management remains optimistic about the company's outlook, maintaining full-year guidance unchanged, with projected net revenue growth of 11.3% for FY26, supported by resilient global payment trends and strong growth in CMS and VAS [7][16]. Financial Summary - For FY26, Visa expects net revenue of US$44.52 billion, with net profit projected at US$24.32 billion and diluted EPS at US$12.93, reflecting a growth rate of 12.7% [2][3]. - Operating expenses in 1Q FY26 rose by 16.2% year-over-year, influenced by unfavorable foreign exchange impacts and increased marketing expenses [3][11]. - The report highlights ongoing share repurchases totaling approximately US$3.8 billion and cash dividends of about US$1.3 billion, reinforcing Visa's commitment to shareholder returns [3][11].

Investment Rating - The report maintains an "Outperform" rating for Sunny Optical Technology [2][10][17] Core Insights - Sunny Optical is expected to achieve attributable net profit of RMB 45.89–47.24 billion in 2025, representing a year-on-year increase of 70% to 75%, significantly above Bloomberg consensus of RMB 35.39 billion. This upside is primarily driven by a one-off investment gain of approximately RMB 9.19 billion from an equity transfer for a stake in Goertek Optics. Excluding this non-recurring item, the core attributable net profit is estimated to be RMB 36.7–38.05 billion, supported by the ongoing premiumization of smartphone camera specifications [3][13] - The company continues to benefit from the upgrade of camera specifications in flagship and mid-to-high-end smartphones, which is expected to enhance both average selling price (ASP) and gross margin for handset lenses and camera modules [4][14] Summary by Relevant Sections Handsets - Despite ongoing headwinds from rising memory costs, the trend of optical upgrades remains intact. The company is well-positioned to benefit from the adoption of higher-value products such as variable aperture and periscope cameras, which will drive ASP and margin expansion [4][14] Automotive - The adoption of intelligent driving technologies is expected to significantly boost the company's automotive lens and module businesses. The average number of cameras per vehicle is projected to increase, with high-end vehicles already equipped with around 12 cameras [5][15] XR & IoT - The company maintains its global leadership in imaging modules for smart glasses, with strong growth in revenue from handheld imaging devices. The rapid expansion of AI and AR glasses is anticipated to be a key growth driver in the coming years [6][16] Valuation - The estimated EPS for 2025-2027 is revised to RMB 4.23, 3.86, and 4.19 respectively. Based on a P/E ratio of 19.6x for 2026, the target price is set at HKD 85.24 [6][17]

Investment Rating - The report assigns a positive outlook on China Medical System Holdings, indicating a potential for significant revenue growth from the newly approved ruxolitinib cream [1][3]. Core Insights - The approval of ruxolitinib cream for treating non-segmental vitiligo is expected to drive substantial sales growth, with management projecting revenues of at least CNY 500 million in 2026 and doubling in 2027, reaching a peak of no less than CNY 6 billion within 4-5 years [3][11]. - The cream is positioned to fill a market gap due to the limitations of existing therapies for vitiligo, with a strong demand from patients willing to pay for better efficacy and fewer side effects [4][12]. - The company has initiated pilot applications of the cream in Hainan, with over 7,700 patients already using it before formal approval, indicating strong early adoption [2][10]. Summary by Sections Product Approval and Market Strategy - On January 30, the company’s subsidiary Dermavon received approval from the NMPA for ruxolitinib cream, which is an innovative formulation for treating non-segmental vitiligo in patients aged 12 and above [1][8]. - The company has established exclusive rights for the development and commercialization of the product in several regions, including Mainland China and Southeast Asia [1][8]. Market Potential and Revenue Projections - Management anticipates that the cream will generate revenues of at least CNY 500 million in 2026, with expectations to double in 2027 and reach a peak revenue of no less than CNY 6 billion [3][11]. - The pricing strategy indicates that the listed price will be lower than the previous pilot price of CNY 6,800 per tube [3][11]. Competitive Landscape - Existing treatments for vitiligo have clinical limitations, and ruxolitinib cream is expected to provide a more effective solution, particularly for patients with facial involvement [4][12]. - The cream's efficacy has been supported by real-world data from the Hainan pilot zone, aligning with international clinical study results [4][12]. Future Developments - The company is also focusing on the potential use of ruxolitinib cream for mild-to-moderate atopic dermatitis, with plans to submit a marketing application soon [4][13].

Investment Rating - The report indicates a bullish stance on the energy storage sector, highlighting it as the most favored sector for investment in 2026 due to expected high growth [6][1]. Core Insights - The energy storage industry is anticipated to experience significant growth in 2026, driven by the recent implementation of the capacity tariff policy and adjustments in lithium carbonate prices, which enhance the valuation attractiveness of energy storage companies [6][1]. - The capacity tariff policy, issued by the National Development and Reform Commission and the National Energy Administration, clarifies the pricing mechanism for new-type energy storage, establishing its market position and accelerating nationwide implementation [9][3]. Summary by Sections Weekly Recommendation Logic - The energy storage sector is expected to see high certainty growth in 2026, making it a top investment choice. Recent underperformance is attributed to seasonal demand and rising raw material prices, but valuations have become attractive post-adjustment [6][1]. - The release of the capacity tariff policy and corrections in lithium carbonate prices are key reasons for the positive outlook on the energy storage sector [6][1]. Weekly Recommended Portfolio - Top Picks: Contemporary Amperex Technology Co., Limited (CATL), Sungrow Power Supply Co., Ltd., EVE Energy Co., Ltd., Hyperstrong Energy Storage Technology Co., Ltd. [7][2]. - Sustained Picks: Tsugami Machinery (China) Co., Ltd., Sunwoda Electronic Co., Ltd., Shenzhen Sinexcel Electric Co., Ltd., CALB Group Co., Ltd., Sichuan Fulin Precision Machinery Co., Ltd., Jiangsu Longpan Technology Co., Ltd. [7][2]. Commentary on the Capacity Tariff Policy - The capacity tariff policy categorizes the pricing mechanism for various energy sources, including new-type energy storage, based on local coal-fired power standards and peak-shaving capacity [8][3]. - The policy aims to establish a clear development direction and tariff formulation methodology, which is significant for the national development of the energy storage industry [9][3].

Investment Rating - The report assigns an "Outperform" rating to multiple companies in the discretionary consumption sector, including Nike, Li Ning, Midea Group, JD Group, Haier Smart Home, Gree Electric, Anta Sports, and many others [1]. Core Insights - The discretionary consumption sector has experienced a significant pullback due to the hawkish stance of the Federal Reserve, leading to a decline in global asset prices [4][13]. - The report highlights that the domestic sportswear sector has shown resilience, with a weekly increase of 0.6%, while other sectors such as luxury goods and cosmetics have faced declines [5][15]. - The report notes that various sub-sectors within discretionary consumption have performed differently, with gold and jewelry being the top performers in the recent weeks [4][13]. Summary by Relevant Sections Weekly Performance Review - The report details the weekly performance of various sectors, indicating that domestic sportswear outperformed others with a 0.6% increase, while luxury goods saw a decline of 5.8% [4][13]. - Monthly performance shows gold and jewelry leading with a 14.8% increase, while luxury goods and overseas sportswear faced significant declines [4][13]. Sector Analysis - The domestic sportswear sector's growth is attributed to increased demand for warm clothing due to colder weather and strategic partnerships, such as Anta Sports' acquisition of a stake in PUMA [6][15]. - The credit card sector experienced mixed results, with Mastercard performing well while Visa and American Express faced declines due to varying financial performance [15]. - The retail sector saw a decline of 1.4%, with some companies like China Resources Vanguard performing well due to favorable policies [15]. Valuation Analysis - The report indicates that the expected PE ratios for various sectors in 2025 are below their historical averages, suggesting potential investment opportunities [11][18]. - For instance, the expected PE for the domestic sportswear sector is 13.4 times, which is 70% of its past five-year average [11][18].

Investment Rating - The report maintains an "Outperform" rating for multiple companies in the healthcare sector, including BeiGene, JD Health, WuXi Biologics, and others, while China National Pharmaceutical Group is rated "Neutral" [1]. Core Insights - The Hong Kong healthcare sector experienced a broad-based correction due to capital pressures, with pharmaceutical distribution remaining relatively stable [4][28]. - The Hang Seng Healthcare Index fell by 3.0% this week, underperforming the Hang Seng Index by 5.4 percentage points, but has gained 8.6% year-to-date, outperforming the Hang Seng Index by 1.7 percentage points [14][27]. - The top five gainers in the sector included Leads Biolabs-B (+19.3%), Sihuan Pharmaceutical (+17.9%), and Tigermed (+7.6%), while the bottom five decliners included Medlive Technology (-16.2%) and Laekna-B (-14.1%) [4][29]. Summary by Sections Market Performance - The report indicates that various sub-sectors within the healthcare market have experienced declines, with pharmaceutical distribution down by 0.3%, internet healthcare down by 2.1%, and medical devices down by 5.0% [4][28]. Company Updates - Rongchang Biopharmaceutical announced a revenue forecast of 3.25 billion yuan for 2025, representing a year-on-year increase of 89%, and has turned a profit [11]. - A collaboration agreement was signed between CSPC Pharmaceutical and AstraZeneca, involving a total payment of $18.5 billion for the licensing of GLP-1 long-acting assets [11]. - AstraZeneca plans to invest $15 billion in China by 2030, focusing on expanding drug manufacturing and R&D capabilities [12]. - Kangzheng Pharmaceutical's lebrikizumab cream has been approved for the treatment of non-segmental vitiligo in patients aged 12 and older [12]. Regulatory Developments - The National Health Commission approved a pilot program for internet-based first consultations in Beijing, which is expected to accelerate prescription outflow [13].